Schizophrenia is an often disabling psychiatric disease whose core treatment consists of years up to a lifetime of treatment with antipsychotics (older typical antipsychotics or newer atypical antipsychotics). With at least ten different atypical antipsychotic molecules available in most major markets under study (United States, France, Germany, Italy, Spain, United Kingdom, Japan), as well as typical antipsychotic options, new entrants must differentiate themselves to garner a foothold in the market. Sales of premium-priced emerging therapies and the continued uptake of long-acting depot formulations of atypical antipsychotics will not overcome sales of top-selling antipsychotics lost to generic erosion during our 2015-2025 study period. The schizophrenia market will experience incremental growth from approximately $5.5 billion in 2015 to over $6.0 billion in 2016, due to the launches and continued uptake of newer-to-market agents; however, major-market sales will decline to $5.4 billion through 2022 before leveling out at approximately $5.5 billion through the end of the forecast period, owing to the generic erosion of key players across the major markets. Key therapies that launched in the United States at the beginning of the forecast period and will be among those notably contributing to buoying the market include Otsuka/Lundbeck's oral atypical antipsychotic brexpiprazole (Vraylar) and two depot formulations of existing antipsychotics, Janssen's paliperidone palmitate three-month formulation (Invega Trinza/Trevicta) and and Alkerme’s aripiprazole lauroxil (Aristada). Emerging therapies in development include two new atypical antipsychotics, Allergan/Gedeon Richter/Mitsubishi Tanabe Pharma’s cariprazine (Vraylar; already launched in the United States) and Alkermes’ ALKS-3831, and one new depot formulation of risperidone, Indivior’s RBP-7000.

Related Reports

Schizophrenia - Special Topics - Special Topics Evolving Market Dynamics In Schizophrenia US

The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primaril...

View Details

Schizophrenia - Special Topics - Special Topics: Agitation In Bipolar And Schizophrenia (US)

Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or...

View Details

Schizophrenia - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

Schizophrenia is an often disabling psychiatric disease that usually requires long-term treatment. The primary goals of medical treatment for schizophrenia are to reduce the frequency and severity...

View Details

Schizophrenia - Unmet Need - Detailed, Expanded Analysis (Cognitive Impairment)

Although the schizophrenia drug market is crowded, no pharmacological agents are approved specifically to treat cognitive impairment associated with schizophrenia (

View Details